Abstract 485P
Background
Afatinib is indicated for the treatment of EGFR mutation-positive (M+) non-small cell lung cancer (NSCLC). LUX-Lung trials have demonstrated that afatinib significantly improved progression-free survival (PFS) compared with chemotherapy. We report results from a retrospective study of first-line afatinib in Korean patients with EGFR M+ NSCLC in real-world setting of two hospitals in South Korea.
Methods
Clinical data of Korean patients with stage IV EGFR M+ NSCLC who received first-line afatinib treatment in Pusan National University Yangsan Hospital and Pusan National University Hospital between February 2015 to December 2016 were obtained. Objective response rate (ORR), disease control rate (DCR), PFS, and tolerability were assessed. The treatment response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). PFS was estimated by Kaplan-Meier method and the differences in survival were assessed by log-rank test.
Results
A total of 99 eligible patients were enrolled for analysis. Mean age was 68 years (range: 35-83 years) and 56.6% were female. A total of 96.0% patients were histologically diagnosed with adenocarcinoma with 52.0% brain metastases (BM). ORR was 63.4% and DCR was 93.5%. Intracranial response was 69.6% in patients treated with afatinib plus local therapy and 55.0% with afatinib therapy alone. Median PFS reached 15.1 (95% CI: 12.6-17.4) months in overall, 12.6 (9.9-14.5) months in exon 19 deletion, 16.9 (12.5-21.1) months in exon 21 L858R mutation, 13.1 (1.9 to 22.3) months in rare mutations, 18.6 (14.9-24.2) months in BM absent, and 12.2 (10.9-15.2) months BM present. There is no significantly difference between PFS either by mutation types or by BM status. The most common Grade ≥3 side effects were skin rash/acne (15.2%), and diarrhea (10.1%).
Conclusions
This study indicates that the clinical outcomes achieved with first-line afatinib in Korean patients in real-world setting appear to be better than observed from the LUX-Lung studies. Afatinib can also provide a good intracranial response in patients with brain metastases regardless of whether or not they also receive local treatment.
Clinical trial identification
Editorial acknowledgement
Dr. Luke for the review and helpful comments for this study.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Presenter: Raimkul Karakulov
Session: Poster display session
Resources:
Abstract
275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
Presenter: Gia Nguyen Hoang
Session: Poster display session
Resources:
Abstract
276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
Presenter: GEDALA Veni Prasanna
Session: Poster display session
Resources:
Abstract
277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
Presenter: Zeeshan Ahmed
Session: Poster display session
Resources:
Abstract
278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
Presenter: Gautamjeet Mangat
Session: Poster display session
Resources:
Abstract
280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
Presenter: Kundan Mishra
Session: Poster display session
Resources:
Abstract
281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
Presenter: Jing Sun
Session: Poster display session
Resources:
Abstract
282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
Presenter: Nidh Gupta
Session: Poster display session
Resources:
Abstract
283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
Presenter: Jinhyun Cho
Session: Poster display session
Resources:
Abstract